特發性膜性腎臟病（IMN）：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 受診斷率提高、基於生物標記的檢測以及靶向免疫療法的日益普及的推動，全球 IMN 市場預計將穩步擴張。
• 預計到 2035 年，IMN 市場規模將達到約 10 億美元，這主要得益於新型標靶治療的出現以及疾病識別準確性的提高。
• 推動市場成長的因素如下：
• Rituximab使用量的增加以及新型B細胞標靶治療的出現
• 擴大基於生物標記的疾病監測和個人化治療策略的應用。
• 擴大抗CD20療法和新型免疫調節療法的臨床開發
• 未來市場成長將取決於下一代精準療法的進步、復發預防策​​略的改進以及針對性自體免疫腎病變的治療。

特發性膜性腎臟病(IMN) 的新治療方法及對 TPP 的深入研究

Thelansis 發布的《特發性膜腎臟病(IMN) 新興治療方法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026》全面分析了該適應症的關鍵新興治療方法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見 (KOL) 的領導者見解。

特發性膜腎臟病（IMN）概述

特發性膜性腎臟病（IMN）是一種慢性自體免疫腎絲球疾病，也是成人腎病變症候群的主要病因之一。其特徵是免疫複合物沉積於腎小球基底膜，導致足細胞損傷和腎臟濾過功能受損。此病主要由針對磷脂酶A2受體（PLA2R）的自身抗體介導，大多數患者體內均可檢測到此類抗體，但涉及其他抗原（如THSD7A）的病例則較為少見。

患者通常表現為腎病症候群，伴隨嚴重蛋白尿、低白蛋白血症、水腫和高血脂症，且血栓性栓塞症和進行性慢性腎臟病的風險顯著增加。診斷主要依據切片檢查觀察和血清學檢測抗PLA2R抗體，後者也可作為監測疾病活動度和治療進展的重要生物標記。

治療初期著重於支持性治療，包括腎素-血管張力素-醛固酮系統（RAAS）阻斷、血壓控制、血脂管理、以及適當的抗凝血治療。利Rituximab因其優於傳統的Cyclophosphamide方案和Calcineurin抑制劑的療效和安全性，正日益受到關注，成為一線免疫抑制療法。新型抗CD20療法和先進的免疫學方法進一步擴展了難治性或復發性疾病的治療選擇。儘管治療方法取得了進展，但疾病復發、抗藥性以及進展為慢性腎臟病仍然是主要的臨床挑戰。

主要亮點

• IMN 仍然是成人腎病症候群的主要原因之一，並且與抗 PLA2R 自體抗體密切相關。
• 進行性蛋白尿和慢性腎臟病仍是長期腎臟疾病的重要因素。
• Rituximab日益成為中高危險疾病的第一線免疫抑制療法。
• 新型抗 CD20 療法和基於生物標記的治療策略正在擴大難治性疾病的治療選擇。
• 精準腎臟病學和基於抗體的疾病監測技術的日益普及，正在改善疾病的長期管理。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 主要企業
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Idiopathic Membranous Nephropathy (IMN) Emerging Therapy and TPP Insights

Thelansis's "Idiopathic Membranous Nephropathy (IMN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Membranous Nephropathy (IMN) Overview

Idiopathic membranous nephropathy (IMN) is a chronic autoimmune glomerular disease and a leading cause of nephrotic syndrome in adults, characterized by immune complex deposition along the glomerular basement membrane leading to podocyte injury and impaired renal filtration function. The disease is primarily mediated by autoantibodies against phospholipase A2 receptor (PLA2R), which are detected in the majority of patients, while additional antigens such as THSD7A account for a smaller subset of cases.

Patients typically present with nephrotic syndrome, including heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia, with significant risk of thromboembolic events and progressive chronic kidney disease. Diagnosis is based on renal biopsy findings together with serological detection of anti-PLA2R antibodies, which also serve as important biomarkers for disease activity and treatment monitoring.

Management initially focuses on supportive therapy including RAAS blockade, blood pressure control, lipid management, and anticoagulation where appropriate. Rituximab has emerged as the preferred first-line immunosuppressive therapy due to its favorable efficacy and safety profile compared with traditional cyclophosphamide-based regimens and calcineurin inhibitors. Emerging anti-CD20 therapies and precision immunologic approaches are further expanding treatment options for refractory or relapsing disease. Despite therapeutic advances, disease relapse, treatment resistance, and progression to chronic kidney disease continue to represent major clinical challenges.

Key Highlights

• IMN remains one of the leading causes of adult nephrotic syndrome and is strongly associated with anti-PLA2R autoantibodies.
• Progressive proteinuria and chronic kidney disease continue to contribute significantly to long-term renal morbidity.
• Rituximab has increasingly become the preferred first-line immunosuppressive therapy in moderate-to-high-risk disease.
• Emerging anti-CD20 therapies and biomarker-guided treatment strategies are expanding treatment options in refractory disease.
• Increasing adoption of precision nephrology and antibody-guided disease monitoring is improving long-term disease management.

Market Overview

• The global IMN market is expected to witness steady expansion driven by increasing diagnosis rates, biomarker-based testing, and growing adoption of targeted immunotherapies.
• IMN market is projected to reach nearly USD 1 billion by 2035, supported by the launch of emerging targeted therapies and improved disease identification.
• Market growth is supported by:
• Rising utilization of rituximab and emerging B-cell-targeted therapies
• Increasing use of biomarker-guided disease monitoring and personalized treatment strategies
• Expanding clinical development of anti-CD20 and novel immunomodulatory therapies
• Future market growth will depend on next-generation precision therapies, improved relapse prevention strategies, and advancements in targeted autoimmune kidney disease management.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)